|
Patent landscape, scope, and claims: |
US Patent 7,538,116 (Gepirone) Claims Scope and US Patent Landscape for Treating Sexual Dysfunction
Executive summary
- US 7,538,116 claims a method-of-treatment using gepirone (short-term or long-term therapy) for sexual dysfunction categorized as hypoactive sexual desire disorder, orgasmic disorder, or sexual arousal disorder, including subsets tied to female/male sexual dysfunction and comorbid psychiatric conditions (major depression, atypical depression, anxiety, panic disorder, drug abuse).
- The claim set is broad at the “drug + indication + patient population” level and does not appear to be limited by dose, formulation, route, titration, treatment duration specifics, or specific diagnostic instruments.
- From an enforceability and design-around perspective, the primary potential “attack” points are (i) diagnostic/clinical mapping between the patent’s “sexual dysfunction” categories and DSM-style definitions used in litigation, and (ii) material claim construction around whether the method requires treatment of a formally diagnosed disorder versus symptoms, plus (iii) whether the accused regimen uses gepirone as the active agent.
- For a US-focused freedom-to-operate (FTO), the core competitive landscape is: (a) other gepirone method claims for depression/anxiety, (b) other gepirone method claims for sexual dysfunction, and (c) alternative agents targeting HSDD/orgasmic/arousal disorders that could launch without needing gepirone claims.
What patents protect gepirone methods for treating sexual dysfunction (US 7,538,116 scope)?
Short answer: US 7,538,116 protects a method of treatment that combines gepirone with a defined set of sexual disorder types. Its coverage is keyed to indication selection more than to chemistry, formulation, or manufacturing.
Claim type and what it covers
US 7,538,116 is a US method-of-use claim. That means:
- Infringement is driven by using gepirone to treat the claimed sexual dysfunction in a person in need.
- Market exclusivity for a regimen typically depends on whether the defendant’s labeling, promotion, clinical use, or regimen instructions correspond to the claimed method.
- If gepirone is marketed for another indication, method-of-use risk can still arise through off-label use in the presence of specific intent, labeling, or promotion (depending on proof standards in the forum).
Key structural elements of claim 1
Claim 1 has five major limitations:
- Administering gepirone
- “To a person in need of treatment”
- “An effective amount”
- Short-term or long-term therapy (duration is not a limiting variable)
- Treating sexual dysfunction that is “selected from”:
- hypoactive sexual desire disorder
- orgasmic disorder
- sexual arousal disorder
Because claim 1 uses “selected from the group consisting of,” it is cleanly enumerated: the claim’s covered sexual disorder must fall within those three buckets.
Claim 1 strength levers
- Active ingredient linkage: “administering … gepirone” narrows to gepirone-based therapy. This is a strong narrowing element for the patentee, but it also creates a clear design-around path: use an alternative active (or possibly a different compound not considered gepirone).
- Duration not constrained: “short-term or long-term therapy” broadens operational coverage across treatment patterns.
- Effective amount is generic: absent dose or dosing schedule constraints, “effective amount” tends to be difficult to design around unless the accused regimen is demonstrably non-therapeutic for the claimed disorders.
Claim 1 claim construction pressure points
The likely dispute zones in litigation typically involve:
- What counts as a “sexual disorder” under the claim categories (clinical criteria vs symptom-based diagnosis).
- Whether the accused therapy was intended for treating one of the enumerated disorders, not another sexual complaint.
- Whether “person in need of treatment” requires formal diagnosis or whether symptom presence suffices.
How broad are the dependent claims in US 7,538,116 (orgasmic vs HSDD vs arousal, female/male, depression/anxiety)?
Short answer: Dependent claims 2–6 add disorder sub-selection and sex context; dependent claims 7–11 add psychiatric and behavioral comorbidity conditions. These are narrowing limitations relative to claim 1, but each is still operationally broad because no dose, route, or protocol details are included.
Dependent claims 2–4: selecting the sexual disorder subtype
- Claim 2: sexual dysfunction is orgasmic disorder
- Claim 3: sexual dysfunction is hypoactive sexual desire disorder (HSDD)
- Claim 4: sexual dysfunction is sexual arousal disorder
These claims likely track how clinicians code and treat sexual dysfunction categories. They can matter in cases where:
- The defendant treats libido/sexual desire or arousal generally, but the evidence disputes which DSM-equivalent diagnosis applies.
- The labeling or promotional materials mention “low desire” or “pain with arousal” but not the enumerated disorders as such.
Dependent claim 5–6: female vs male sexual dysfunction
- Claim 5: sexual dysfunction is female sexual dysfunction
- Claim 6: sexual dysfunction is male sexual dysfunction
These are additional narrowing variables. They can become central if accused regimens target:
- a population that includes both sexes, or
- a specific patient segment with different indications and evidence.
Dependent claims 7–11: comorbidity-limited subgroups
- Claim 7: major depression
- Claim 8: atypical depression
- Claim 9: anxiety
- Claim 10: panic disorder
- Claim 11: drug abuse
These convert claim 1’s “person in need” into a person with comorbid psychiatric/behavioral conditions. Practically:
- They can reduce scope against a defendant who treats sexual dysfunction without targeted psychiatric comorbidity.
- They also provide the patentee multiple routes to establish infringement if evidence shows gepirone was administered in patients with those comorbidities alongside sexual dysfunction treatment.
No dosing/formulation limits
Nothing in the text provided constrains:
- dose strength (mg)
- titration
- frequency
- route (oral is assumed for gepirone but not required in the claim text)
- treatment duration beyond “short-term or long-term”
- formulation type (immediate release vs controlled release)
- concomitant medications
That absence pushes the landscape toward indication-driven infringement rather than product-specific infringement.
What design-arounds exist versus US 7,538,116 (gepirone vs alternatives, diagnosis framing, regimen selection)?
Short answer: The most direct design-around is not using gepirone. Secondary design-arounds involve not treating the enumerated sexual disorders as such (or avoiding evidence/intent that the regimen treats those disorders) and avoiding key comorbidity subsets if relying on dependent claim narrowing.
Primary design-around: avoid gepirone
If the therapy uses a different active ingredient, the “administering gepirone” limitation is not met. For a typical US method-of-use patent, this is the cleanest avoidance.
Indication and evidence design-around
Because the claims are tied to sexual dysfunction selection and “person in need,” defendants often focus on:
- clinical documentation that the condition is different from the enumerated disorders, or
- treatment being aimed at adjacent symptoms rather than the diagnosed disorders named in the claims.
Note: the claims do not require a specific DSM code or instrument in the provided claim language, which can make “diagnosis-only” defenses harder if a factfinder equates clinical manifestations with the claimed disorder labels.
Dependent-claim containment strategy
For litigating or FTO where exposure is through claims 7–11, a defendant could position:
- no major depression/anxiety/panic disorder/drug abuse was present or relevant to the sexual dysfunction treatment,
- or the treatment regimen was used for patients outside those subgroups.
What is the Orange Book status of US 7,538,116 and how does it affect generic entry risk?
No complete answer possible from the information provided.
A correct Orange Book status requires the drug product identity (NDC, listed active ingredient strength, dosage form, and Orange Book publication listings) and the patent-to-product mapping. The claim text alone does not establish those linkages.
How many US patents are likely in the gepirone method-of-use estate, and how are they positioned around sexual dysfunction?
No complete answer possible from the information provided.
A complete count and mapping across the US patent estate requires the patent family identifiers, assignee, and a docket-level search for:
- other method-of-use claims for sexual dysfunction with gepirone,
- method claims for depression/anxiety that could overlap with the comorbidity-limited dependents (claims 7–11),
- and potentially earlier blocking patents on gepirone itself, dosing, or combination regimens.
Which companies are likely challenging gepirone sexual dysfunction claims via Paragraph IV or biosimilar routes?
No complete answer possible from the information provided.
Paragraph IV challenges require a known FDA-approved product and ANDA landscape. Biosimilars are not applicable to gepirone unless the underlying product is biologic, which it is not indicated to be. The necessary FDA and litigant-specific data is not present in the provided materials.
Does US 7,538,116 cover combination therapy, off-label use, or specific dosing protocols?
Short answer: Based on the provided claim language, the claims cover administration of gepirone for the enumerated sexual dysfunction disorders, with no explicit restrictions on combinations, dosing protocol, or route.
Combination therapy
The independent claim does not exclude co-therapies. If an accused regimen includes gepirone with other agents but still administers an “effective amount” of gepirone for the claimed sexual dysfunction, claim 1 can still be implicated.
Off-label use
Method-of-use claims are typically enforceable against actual medical use that meets claim limitations, regardless of label (subject to proof). Since the claim requires only the act of administering gepirone for the specified sexual dysfunction categories, off-label use remains a potential infringement theory.
Dosing and duration
“Short-term or long-term therapy” removes duration-based design-around room. Without dose boundaries, “effective amount” could become an evidentiary fight on whether the administered amount was therapeutically effective for the asserted disorder.
How does US 7,538,116 compare with other method-of-use patents for HSDD, orgasmic disorder, and arousal disorders?
No complete answer possible from the information provided.
A comparison requires identifying:
- alternative patents covering similar sexual dysfunction indications,
- whether those patents are for other actives (e.g., SSRIs, dopaminergic agents, flibanserin-related estates, bremelanotide-related estates, etc.),
- and the claim limitations (diagnostic definitions, trial evidence, patient populations, and dosing/formulation constraints).
What patent litigation tactics matter for US 7,538,116 (claim construction, proof of intent, comorbidity evidence)?
Short answer: Litigation is likely to focus on claim construction around “sexual dysfunction selected from” and proof that gepirone was administered to treat that specific disorder in a person meeting the asserted comorbidity subset (for dependent claims).
Core litigation issues likely to recur
- Disorder mapping: whether the treated condition matches hypoactive sexual desire disorder, orgasmic disorder, or sexual arousal disorder.
- Comorbidity linkage for dependent claims: major depression/atypical depression/anxiety/panic disorder/drug abuse presence and relevance.
- “Effective amount” evidence: dosing records, clinical outcomes, and expert interpretation.
- Short-term vs long-term: usually not a dispute because both are covered, but defendants may still attempt to frame the regimen as outside “therapy” (e.g., incidental or discontinuous use).
Key Takeaways
- US 7,538,116 is an indication-driven method-of-use patent covering gepirone administered to treat three enumerated sexual dysfunction categories: HSDD, orgasmic disorder, and sexual arousal disorder.
- Dependent claims narrow by (i) choosing a specific sexual disorder and (ii) adding female/male and psychiatric/behavioral comorbidity limitations (major depression, atypical depression, anxiety, panic disorder, drug abuse).
- The claim language is broad on regimen duration and operationally broad on dosing/formulation/route, increasing reliance on evidentiary proof of (a) patient diagnosis mapping and (b) the therapeutic intent and effect of gepirone administration.
FAQs
- Does US 7,538,116 require a specific DSM diagnosis code to prove infringement of HSDD or orgasmic disorder?
- If a patient has both anxiety and low sexual desire, does that automatically satisfy claim 9 and claim 3 (arousal/HSDD subtype) depending on the claimed disorder label used in evidence?
- Can a regimen that includes gepirone plus other psychotropics still infringe US 7,538,116 if gepirone is administered for the claimed sexual dysfunction?
- What evidence is most persuasive to establish “effective amount” of gepirone for the claimed sexual dysfunction categories?
- How do female vs male sexual dysfunction dependent claims typically affect infringement theories when a product is used in mixed-sex populations?
References (APA)
- User-provided claim text for US Patent 7,538,116 (gepirone sexual dysfunction method-of-treatment claims 1–11).
More… ↓
⤷ Start Trial
|
